^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Nov 2026
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1d
    HIPEC: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2d
    COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2/3, N=582, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2d
    NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    3d
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    3d
    NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    5d
    Clinical features and outcomes of adult primary retroperitoneal lymphangioma: insights from a high-volume sarcoma center. (PubMed, Front Surg)
    Complete surgical resection demonstrates excellent safety and long-term efficacy, with individualized approach selection based on tumor characteristics. Our findings from this substantial Chinese adult cohort provide valuable insights for managing this uncommon condition.
    Journal
    |
    CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    5d
    Inhibition of P-glycoprotein using photoimmunotherapy in peritoneal metastasis mouse model. (PubMed, Photochem Photobiol)
    PIC-PIT significantly increased intracellular Rhodamine 123 retention, indicating effective reduction of P-gp activity. This study provides the first in vivo evidence that PIT can inhibit P-gp function, offering a promising, targeted approach to overcoming chemoresistance while avoiding the systemic toxicity associated with conventional P-gp inhibitors.
    Preclinical • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
    7d
    PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=10, Recruiting, University of California, Irvine | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    7d
    HERO: Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Nordic Society of Gynaecological Oncology - Clinical Trials Unit | N=350 --> 1000 | Trial completion date: Dec 2028 --> Jul 2032 | Trial primary completion date: Dec 2028 --> May 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    9d
    Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    9d
    Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=1025, Active, not recruiting, Shanghai Gynecologic Oncology Group | Not yet recruiting --> Active, not recruiting | N=4489 --> 1025 | Trial completion date: Mar 2028 --> Jun 2027 | Trial primary completion date: Mar 2028 --> Jun 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Real-world evidence